SciELO - Scientific Electronic Library Online

 
vol.45 issue1Consensus in pediatric rheumatology: part I - criteria definition of inactive disease and remission in juvenile idiopathic arthritis / juvenile rheumatoid arthritisFibromyalgia and infectious stress: possible associations between fibromyalgia syndrome and chronic viral infections author indexsubject indexarticles search
Home Pagealphabetic serial listing  

Revista Brasileira de Reumatologia

Print version ISSN 0482-5004

Abstract

MACHADO, Claudia  and  RUPERTO, Nicolino. Consensus in pediatric rheumatology: part II - definition of clinical improvement in systemic lupus erythematosus and juvenile dermatomyositis. Rev. Bras. Reumatol. [online]. 2005, vol.45, n.1, pp. 14-19. ISSN 0482-5004.  http://dx.doi.org/10.1590/S0482-50042005000100004.

OBJECTIVE: To evaluate the consensus development of the core response variables for disease activity in Juvenile Systemic Lupus Erythematosus (JSLE) and Juvenile Dermatomyositis (JDM) as well as the preliminary definition of improvement for both. METHODS AND RESULTS: The core response domains and variables for JSLE were: 1) disease activity global assessment by the physician = 10 cm VAS; 2) health related to quality of life = CHQ-PF50 physical score; 3) disease activity global assessment by parents/patients = 10 cm VAS; 4) kidney assessment = 24 h proteinuria; 5) global disease activity assessment by a specific and valid tool (SLEDAI or ECLAM). The preliminary definition of improvement for JSLE was: 2 of the 5 measures with at least 50% of improvement and no more than 1 worse by more than 30%, which cannot be the 24 h proteinuria. The core response domains and variables for JDM were: 1) disease activity global assessment by the physician = 10 cm VAS; 2) muscle strength assessment by a specific tool (CMAS - Childhood Myositis Assessment Scale) = 0-52; 3) functional assessment by a valid tool (CHAQ); 4) disease activity global assessment by parents/patients = 10 cm VAS; 5) health related to quality of life (CHQ-PF50 physical score); 6) global disease activity assessment by specific and valid tool (DAS - Disease Activity Score). The preliminary definition of improvement for JDM was: 3 of the 6 measures with at least 20% of improvement and no more than 1 worse by more than 30%, which cannot be the muscle strength by CMAS. CONCLUSIONS: All the variables were tested and have shown good statistical responsiveness and discriminative validity to be used in therapeutic trials.

Keywords : consensus; disease activity; juvenile dermatomyositis; juvenile systemic lupus erythematosus.

        · abstract in Portuguese     · text in Portuguese     · pdf in Portuguese